News

Custom health communications company, StayWell Custom Communications (SCC), a division of MediMedia US, has announced an exclusive strategic alliance with Siteimprove. The alliance is intended to provide value

Amylin, Eli Lilly, and Alkermes have announced long-term, interim results from the Duration-1 study that showed sustained glucose control with weight loss, as well as improvements in systolic

New Phase II data showed that the investigational type 2 diabetes treatment Syncria (albiglutide) has reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly

Novo Nordisk has reported that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and weight, after two years of treatment.  

Amgen has reported the results of a new study comparing Nplate (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura

The findings of two 52-week studies showed that the investigational ultra rapid acting insulin Afresa Inhalation Powder, combined with basal insulin, is comparable to standard of care therapies

VIVUS has reported the glycemic findings from Equate, a phase-III trial evaluating Qnexain non-diabetic, obese patients. After 28 weeks of treatment, blood sugar levels, as measured by hemoglobin

Sanofi-Aventis has come up with the results of a new study – Effects of 1, 2, or 3 prandial injections of insulin glulisine on glycemic control in type

Amylin has announced that the use of mealtime Symlin (pramlintide acetate) injection has improved glucose control, treatment satisfaction and quality of life for patients with type 2 diabetes.